Sequential three-component synthesis of 1,4-bis[triazolo[4,5-d]pyrimidin- 7(6H)-one]piperazines

Article abstract of DOI:10.3987/COM-12-12564

A simple three-component reaction and efficient method is described for the synthesis of 1,4-bis[triazolo[4,5-d]pyrimidin-7(6H)-one]piperazines by a sequential three-component process involving an aza-Wittig reaction/ heterocyclization in the presence of

Full text of DOI:10.3987/COM-12-12564

HETEROCYCLES, Vol. 85, No. 11, 2012
2757
HETEROCYCLES, Vol. 85, No. 11, 2012, pp. 2757 - 2763. © 2012 The Japan Institute of Heterocyclic Chemistry
Received, 3rd August, 2012, Accepted, 30th August, 2012, Published online, 31st August, 2012
DOI: 10.3987/COM-12-12564
SEQUENTIAL THREE-COMPONENT SYNTHESIS OF
1,4-BIS[TRIAZOLO[4,5-d]PYRIMIDIN-7(6H)-ONE]PIPERAZINES
Zheng Dong Fang* and Xian Hong Wei
College of Chemistry and Environmental Engineering, Hubei Normal University,
Huangshi, 435002, P. R. China. E-mail: zdfang2007@163.com
Abstract – A simple three-component reaction and efficient method is described
for the synthesis of 1,4-bis[triazolo[4,5-d]pyrimidin-7(6H)-one]piperazines by a
sequential
three-component
process
involving
an
aza-Wittig
reaction/heterocyclization in the presence of sodium ethoxide as catalyst. The
iminophosphorane 1 reacted with aromatic isocyanate gave carbodiimides 2,
followed by addition of piperazine derivatives to give the corresponding
guanidine intermediates 3. The guanidine intermediates were cyclized in the
presence of catalytic amount of sodium ethoxide to give 1,4-bis[triazolo[4,5-d]-
pyrimidin-7(6H)-one]piperazines 4 in good yields.
In recent years, multicomponent reactions (MCRs) have become important tools in modern preparative
synthetic chemistry because these reactions increase efficiency by combining several operational steps
without any isolation of intermediates or changes in the conditions.1-4 This principle, therefore, is highly
efficient in terms of time as well as resources. Among the known multicomponent reactions to date, the
most valuable reactions are those based on isocyanides. In the development of strategies for the
preparation of heterocycles, the aza-Wittig reaction has proved to be a powerful tool for the synthesis of
fused nitrogen heterocycles.5,6 Triazolo[4,5-d]pyrimidines are widely recognized as pharmaceutically and
biologically useful heterocycles because of their structural similarities to purine bases.7,8 An important
synthetic route for triazolo[4,5-d]pyrimidines in previous reports is the nitrosative cyclization of
5,6-diamino-2-phenylpyrimidin-4(3H)-ones with nitrous acid. 9 However, this method is characterized as
a long reaction time and low yield. Recently, we have been interested in the synthesis of fused
pyrimidinones via aza-Wittig reaction of β-ethoxycarbonyliminophosphorane with aromatic isocyanate
and subsequent reaction with various nucleophiles under mild conditions. As a continuation of our
research for new biologically active heterocycles,10,11 here we wish to report an efficient synthesis of

2758
HETEROCYCLES, Vol. 85, No. 11, 2012
1,4-bis[triazolo[4,5-d]pyrimidin-7(6H)-one]piperazines, a series of compounds which have not been
reported before.
The key iminophosphorane 1 (synthesized according to the literature12) reacted with aromatic isocyanate
to give carbodiimides 2. The reaction proceeded smoothly in THF at room temperature. Then, reaction of
carbodiimides 2 with piperazine derivatives at room temperature gave intermediate guanidines 3 via
initial double nucleophilic addition of piperazine derivatives to the carbodiimide. Even in refluxing
toluene, 3 did not cyclize. However, in dry ethylene chloride and in the presence of a catalytic amount of
EtONa, compounds
3
were converted smoothly to the 1,4-bis[triazolo[4,5-d]pyrimidin-
7(6H)-one]piperazines 4 in satisfactory yields at room temperature (Scheme 1). We found that
heterocyclization occurred via nucleophilic displacement of the neighboring ester ethoxide group to
provide the target compounds 4 by intramolecular hetero conjugate addition annulations. Irrespective of
the fact whether substituted piperazines or unsubstantiated piperazine, the cyclization proceeded very
smoothly in the same regioselectivity. No matter the substituents on the benzene are electron-withdrawing
or electron-donating groups, the cyclization can be completed easily under mild conditions.
Scheme 1
The results are listed in Table 1.
Table 1. Preparation of 1,4-Bis[triazolo[4,5-d]pyrimidin-7(6H)-one]piperazines
Compd.
Ar
R
Yield */%
4a
4b
4c
4d
4e
Ph
Ph
Ph
Ph
Ph
H
87
85
79
74
83
2-Me
2,5-diMe
2,6-diMe
2-Et

HETEROCYCLES, Vol. 85, No. 11, 2012
2759
4f
4g
4h
4i
4-Me-C6H4
4-Me-C6H4
H
82
80
74
75
78
93
87
82
78
81
2-Me
4-Me-C6H4 2,5-diMe
4-Me-C6H4 2,6-diMe
4j
4-Me-C6H4
4-Cl-C6H4
4-Cl-C6H4
2-Et
H
4k
4l
2-Me
4m
4n
4o
4-Cl-C6H4 2,5-diMe
4-Cl-C6H4 2,6-diMe
4-Cl-C6H4
2-Et
*isolated yields based on iminophosphorane 1
In conclusion, we have demonstrated that 1,4-bis[triazolo[4,5-d]pyrimidin-7(6H)-one]piperazines can be
produced via aza-Wittig reaction/heterocyclization in the presence of sodium ethoxide as catalyst. As the
synthetic method reported in this paper starts with readily available compounds and is operationally simple,
it may find some value in organic synthesis.
EXPERIMENTAL
Melting points were determined on an X-4 model digital micro-melting point hot stage apparatus and
were uncorrected. IR spectra were recorded on a Nicolet 7500 NXR infrared spectrometer as KBr pellets
with absorption values given in wave numbers (ν, cm-1). 1H NMR spectra were measured in CDCl3 on a
Varian Mercury Plus 300 (300Hz) spectrometer and chemical shift values were expressed in δ values
(ppm) relative to Me4Si (TMS) as an internal reference (δ = 0). 13C NMR spectra were determined on the
same Varian Mercury Plus 300 spectrometer at 75 MHz. Mass spectral (MS) data were obtained on a
Finnigan LCQ Advantage MAX mass spectrometer. Elementary analyses were taken on a Perkin-Elmer
CHN 2400 elemental analysis instrument. Progress of the reactions was monitored by analytical thin-layer
chromatography (TLC) on glass sheets precoated with UV fluorescent silica gel.
General preparation of 1,4-Bis[triazolo[4,5-d]pyrimidin-7(6H)-one]piperazines 4
Aromatic isocyanate was added (0.006 mol) to the solution of iminophosphorane 1 (0.006 mol) in THF
(10 mL) at 0-5 °C. When the resulting iminophosphorane 1 reacted with aromatic isocyanate,
triphenylphosphine oxide was formed. After the reaction mixture was left unstirred for 5-6 h at 0-5 °C,
the solvent was removed off under reduced pressure and Et2O/petroleum ether (1:2, 12 mL) was added to

2760
HETEROCYCLES, Vol. 85, No. 11, 2012
precipitate triphenylphosphine oxide. Removal of the solvent gave carbodiimides 2, which were used
directly without further purification. Piperazine derivatives (0.003 mol) were added to the solution of 3
prepared above in CH2Cl2 (10 mL). After the reaction mixture was left unstirred for 2-3 h, the solvent was
removed and EtONa in anhydrous EtOH (8 mL, 10%) was added. The mixture was stirred for 3-5 h at
room temperature. The solution was condensed and the residue was recrystallized from EtOH to give the
target compound 4.
1,4-Bis[4-oxo-1,5-diphenyl-1,2,3-triazolo[4,5-d]pyrimidin-2(3H)-yl]piperazine (4a): white crystals;
mp 258-259 °C; IR 3341, 2953, 1718 (C=O), 1527, 1423, 1368 cm-1; 1H NMR (300 MHz, CDCl3) δ 2.62
13
(t, J = 7.0 Hz, 8H), 6.87-7.54 (m, 20H); C NMR (75 MHz, CDCl3)  44.58, 118.05, 124.40, 127.91,
128.50, 128.87, 129.06, 129.45, 129.87, 133.51, 149.38, 155.64, 161.38; ESI-MS m/z 661.25 (M+ + H).
Anal. Calcd for C36H28N12O2: C, 65.44; H, 4.27; N, 25.44. Found: C, 65.29; H, 4.18; N, 25.53.
1,4-Bis[4-oxo-1,5-diphenyl-1,2,3-triazolo[4,5-d]pyrimidin-2(3H)-yl]-2-methylpiperazine (4b): white
1
crystals; mp 273-274 °C; IR 3340, 2932, 1709 (C=O), 1521, 1436, 1359 cm-1; H NMR (300 MHz,
CDCl3)  1.15 (d, J = 6.8 Hz, 3 H), 2.46 (d, J = 7.0 Hz, 2H), 2.56 (t, J = 7.2 Hz, 4H), 2.98 (m, 1 H),
6.86-7.45 (m, 20 H); 13C NMR (75 MHz, CDCl3)  16.32, 42.84, 44.15, 45.55, 46.62, 118.05, 124.40,
127.91, 128.50, 128.87, 129.06, 129.45, 130.96, 133.51, 149.38, 155.64, 161.38; ESI-MS m/z 675.36 (M+
+ H). Anal. Calcd for C37H30N12O2: C, 65.86; H, 4.48; N, 24.91. Found: C, 65.95; H, 4.39; N, 25.01.
1,4-Bis[4-oxo-1,5-diphenyl-1,2,3-triazolo[4,5-d]pyrimidin-2(3H)-yl]-2,5-dimethypiperazine
(4c):
white crystals; mp 281-282 °C; IR 3341, 2942, 1717 (C=O), 1548, 1443, 1371 cm-1; 1H NMR (300 MHz,
CDCl3) 1.18 (d, J = 7.0 Hz, 6 H), 2.55 (d, J = 7.2 Hz, 4H), 3.01 (t, J = 6.2 Hz, 2 H), 6.76-7.35 (m, 20 H);
13C NMR (75 MHz, CDCl3)  16.32, 41.58, 46.96, 118.05, 124.40, 127.91, 128.50, 128.87, 129.06,
129.42, 130.32, 132.34, 149.45, 155.65, 161.37; ESI-MS m/z 689.46 (M+ + H). Anal. Calcd for
C38H32N12O2: C, 66.27; H, 4.68; N, 24.40. Found: C, 66.21; H, 4.73; N, 24.34.
1,4-Bis[4-oxo-1,5-diphenyl-1,2,3-triazolo[4,5-d]pyrimidin-2(3H)-yl]-2,6-dimethylpiperazine
(4d):
white crystals; mp 268-269 °C; IR 3312, 2924, 1718 (C=O), 1524, 1436, 1340 cm-1; 1H NMR (300 MHz,
CDCl3)  1.17 (d, J = 7.0 Hz, 6H), 2.54 (d, J = 7.2 Hz, 4H), 3.02 (t, J = 6.8 Hz, 2 H), 6.76-7.41 (m, 20 H);
13C NMR (75 MHz, CDCl3)  16.60, 44.08, 44.46, 118.21, 124.40, 127.91, 128.50, 128.87, 129.06,
129.42, 130.21, 132.62, 149.33, 155.62, 161.64; ESI-MS m/z 689.43 (M+ + H). Anal. Calcd for
C38H32N12O2: C, 66.27; H, 4.68; N, 24.40. Found: C, 66.23; H, 4.77; N, 24.37.
1,4-Bis[4-oxo-1,5-diphenyl-1,2,3-triazolo[4,5-d]pyrimidin-2(3H)-yl]-2-ethylpiperazine (4e): white
crystals; mp＞300 °C; IR 3318, 2936, 1715 (C=O), 1548, 1450, 1342 cm-1; 1H NMR (300 MHz, CDCl3)
 1.01 (t, J = 7.2 Hz, 3H), 1.37 (m, 2H), 2.54 (d, J = 7.0 Hz, 2 H), 2.57 (t, J = 6.8 Hz, 4H), 6.54-7.33 (m,
20H); 13C NMR (75 MHz, CDCl3)  9.06, 22.97, 41.62, 43.09, 45.56, 53.56, 118.05, 124.40, 127.91,

HETEROCYCLES, Vol. 85, No. 11, 2012
2761
128.50, 128.87, 129.04, 129.23, 139.97, 132.33, 149.63, 155.65, 161.32; ESI-MS m/z 689.45 (M+ + H).
Anal. Calcd for C38H32N12O2: C, 66.27; H, 4.68; N, 24.40. Found: C, 66.28; H, 4.75; N, 24.36.
1,4-Bis[4-oxo-1-phenyl-5-(4-methylphenyl)-1,2,3-triazolo[4,5-d]pyrimidin-2(3H)-yl]piperazine (4f):
white crystals; mp 276-277 °C; IR 3321, 2940, 1708 (C=O), 1551, 1436, 1335 cm-1; 1H NMR (300 MHz,
CDCl3)  2.35 (s, 6H), 2.55 (t, J = 7.0 Hz, 8H), 6.62-7.25 (m, 18H); 13C NMR (75 MHz, CDCl3)  24.56,
45.33, 121.12, 127.91, 128.50, 128.87, 129.06, 129.34, 129.63, 129.91, 132.94, 146.32, 158.36, 164.42;
ESI-MS m/z 689.43 (M+ + H). Anal. Calcd for C38H32N12O2: C, 66.27; H, 4.68; N, 24.40. Found: C,
66.19; H, 4.55; N, 24.50.
1,4-Bis[4-oxo-1-phenyl-5-(4-methylphenyl)-1,2,3-triazolo[4,5-d]pyrimidin-2(3H)-yl]-2-methyl-
piperazine (4g): white crystals; mp 261-262 °C; IR 3332, 2943, 1716 (C=O), 1553, 1435, 1354 cm-1; 1H
NMR (300 MHz, CDCl3)  1.15 (d, J = 6.8 Hz, 3 H), 2.35 (s, 6H), 2.42 (d, J = 7.2 Hz, 2H), 2.51 (t, J =
7.2 Hz, 4H), 2.98 (m, 1 H), 6.66-7.36 (m, 18 H); 13C NMR (75 MHz, CDCl3)  16.32, 24.56, 42.84, 44.15,
45.55, 46.62, 121.01, 127.91, 128.50, 128.86, 129.06, 129.21, 129.47, 130.96, 133.57, 149.35, 155.63,
161.38; ESI-MS m/z 703.36 (M+ + H). Anal. Calcd for C39H34N12O2: C, 66.65; H, 4.88; N, 23.92. Found:
C, 66.57; H, 4.71; N, 24.06.
1,4-Bis[4-oxo-1-phenyl-5-(4-methylphenyl)-1,2,3-triazolo[4,5-d]pyrimidin-2(3H)-yl]-2,5-dimethyl-
piperazine (4h): white crystals; mp 287-288 °C; IR 3342, 2963, 1719 (C=O), 1552, 1452, 1336 cm-1; 1H
NMR (300 MHz , CDCl3)  1.13 (d, J = 7.0 Hz, 6 H), 2.35 (s, 6H), 2.55 (d, J = 7.2 Hz, 4 H), 3.02 (t, J =
13
6.8 Hz, 2 H), 6.49-7.37 (m, 18 H); C NMR (75 MHz, CDCl3)  16.32, 24.56, 42.51, 46.95, 118.07,
127.91, 128.50, 128.87, 129.06, 129.12, 129.42, 130.01, 134.57, 149.45, 155.66, 161.35; ESI-MS m/z
717.51 (M+ + H). Anal. Calcd for C40H36N12O2: C, 67.02; H, 5.06; N, 23.45. Found: C, 66.93; H, 4.97; N,
23.36.
1,4-Bis[4-oxo-1-phenyl-5-(4-methylphenyl)-1,2,3-triazolo[4,5-d]pyrimidin-2(3H)-yl]-2,6-dimethyl-
1
piperazine (4i): white crystals; mp＞300 °C; IR 3332, 2919, 1717 (C=O), 1548, 1466, 1323 cm-1; H
NMR (300 MHz, CDCl3)  1.15 (d, J = 7.0 Hz, 6H), 2.35 (s, 6H), 2.51 (d, J = 7.2 Hz, 4H), 3.04 (t, J = 6.8
Hz, 2 H), 6.61-7.34 (m, 18 H); 13C NMR (75 MHz, CDCl3)  16.60, 24.56, 44.08, 44.46, 118.21, 127.91,
128.50, 128.87, 129.06, 129.12, 129.45, 130.20, 133.62, 149.33, 155.62, 161.64; ESI-MS m/z 717.48 (M+
+ H). Anal. Calcd for C40H36N12O2: C, 67.02; H, 5.06; N, 23.45. Found: C, 66.95; H, 4.97; N, 23.33.
1,4-Bis[4-oxo-1-phenyl-5-(4-methylphenyl)-1,2,3-triazolo[4,5-d]pyrimidin-2(3H)-yl]-2-ethyl-
1
piperazine (4j): white crystals; mp＞300 °C; IR 3332, 2934, 1715 (C=O), 1563, 1442, 1338 cm-1; H
NMR (300 MHz, CDCl3)  1.02 (t, J = 6.8 Hz, 3H), 1.37 (m, 2H), 2.35 (s, 6H), 2.53 (d, J = 7.2 Hz, 2H),
13
2.56 (t, J = 6.8 Hz, 4H), 6.54-7.33 (m, 18H); C NMR (75 MHz, CDCl3)  9.06, 22.97, 24.56, 41.62,
43.09, 45.56, 53.56, 119.35, 127.91, 128.50, 128.87, 129.06, 129.23, 129.49, 139.97, 133.87, 149.62,

2762
HETEROCYCLES, Vol. 85, No. 11, 2012
155.61, 161.37; ESI-MS m/z 717.39 (M+ + H). Anal. Calcd for C40H36N12O2: C, 67.02; H, 5.06; N, 23.45.
Found: C, 66.97; H, 4.98; N, 23.39.
1,4-Bis[4-oxo-1-phenyl-5-(4-chlorophenyl)-1,2,3-triazolo[4,5-d]pyrimidin-2(3H)-yl]piperazine (4k):
1
white crystals; mp＞300 °C; IR 3322, 2912, 1718 (C=O), 1541, 1462, 1328 cm-1; H NMR (300 MHz,
CDCl3) δ 2.65 (t, J = 7.0 Hz, 8H), 6.62-7.25 (m, 18H); 13C NMR (75 MHz, CDCl3)  45.33, 123.15,
127.91, 128.44, 128.85, 129.03, 129.24, 129.81, 130.47, 131.34, 151.64, 157.37, 165.47; ESI-MS m/z
729.51 (M++H). Anal. Calcd for C36H26N12O2Cl2: C, 59.27; H, 3.59; N, 23.04. Found: C, 59.34; H, 3.53;
N, 23.11.
1,4-Bis[4-oxo-1-phenyl-5-(4-chlorophenyl)-1,2,3-triazolo[4,5-d]pyrimidin-2(3H)-yl]-2-methyl-
1
piperazine (4l): white crystals; mp＞300 °C; IR 3318, 2931, 1716 (C=O), 1523, 1454, 1365 cm-1; H
NMR (300 MHz, CDCl3)  1.11 (d, J = 6.8 Hz, 3H), 2.54 (d, J = 7.0 Hz, 2H), 2.51 (t, J = 7.2 Hz, 4H),
13
2.98 (m, 1 H) , 6.43-7.25 (m, 18 H); C NMR (75 MHz, CDCl3)  16.32, 42.84, 44.15, 45.55, 46.62,
123.05, 127.93, 128.50, 128.88, 129.06, 129.25, 129.85, 130.46, 131.51, 151.38, 157.64, 165.32; ESI-MS
m/z 743.26 (M++H). Anal. Calcd for C37H28N12O2Cl2: C, 59.76; H, 3.80; N, 22.60. Found: C, 59.85; H,
3.77; N, 22.52.
1,4-Bis[4-oxo-1-phenyl-5-(4-chlorophenyl)-1,2,3-triazolo[4,5-d]pyrimidin-2(3H)-yl]-2,5-dimethyl-
1
piperazine (4m): white crystals; mp＞300 °C; IR 3312, 2923, 1719 (C=O), 1525, 1449, 1361 cm-1; H
NMR (300 MHz, CDCl3)  1.11 (d, J = 7.0 Hz, 6 H), 2.54 (d, J = 7.2 Hz, 4H), 3.02 (t, J = 6.2 Hz, 2 H),
6.41-7.28 (m, 18 H); 13C NMR (75 MHz, CDCl3)  16.32, 41.58, 46.96, 118.05, 127.91, 128.50, 128.87,
129.06, 129.25, 129.88, 130.47, 131.46, 149.38, 155.64, 161.38; ESI-MS m/z 757.29 (M++H). Anal.
Calcd for C38H30N12O2Cl2: C, 60.24; H, 3.99; N, 22.19. Found: C, 60.31; H, 3.92; N, 22.12.
1,4-Bis[4-oxo-1-phenyl-5-(4-chlorophenyl)-1,2,3-triazolo[4,5-d]pyrimidin-2(3H)-yl]-2,6-dimethyl-
1
piperazine (4n): white crystals; mp＞300 °C; IR 3331, 2917, 1717 (C=O), 1547, 1561, 1383 cm-1; H
NMR (300 MHz, CDCl3)  1.12 (d, J = 7.0 Hz, 6H), 2.52 (d, J = 7.2 Hz, 4H), 3.01 (t, J = 6.8 Hz, 2 H),
6.46-7.27 (m, 18 H); 13C NMR (75 MHz, CDCl3)  16.60, 44.08, 44.46, 118.05, 127.91, 128.50, 128.87,
129.06, 129.45, 129.95, 130.11, 131.51, 149.34, 155.61, 161.32; ESI-MS m/z 757.32 (M++H). Anal.
Calcd for C38H30N12O2Cl2: C, 60.24; H, 3.99; N, 22.19. Found: C, 60.27; H, 3.94; N, 22.10.
1,4-Bis[4-oxo-1-phenyl-5-(4-chlorophenyl)-1,2,3-triazolo[4,5-d]pyrimidin-2(3H)-yl]-2-ethyl-
1
piperazine (4o): white crystals; mp＞300 °C; IR 3332, 2941, 1715 (C=O), 1533, 1447, 1341 cm-1; H
NMR (300 MHz, CDCl3)  0.98 (t, J = 7.0 Hz, 3 H), 1.38 (m, 2 H), 2.53 (d, J = 7.2 Hz, 2 H), 2.56 (t, J =
6.8 Hz, 4H), 6.54-7.36 (m, 18 H); 13C NMR (75 MHz, CDCl3)  9.06, 22.97, 41.62, 43.09, 45.56, 53.56,
118.05, 127.91, 128.50, 128.87, 129.06, 129.45, 130.07, 130.96, 131.51, 149.37, 155.64, 161.47; ESI-MS

HETEROCYCLES, Vol. 85, No. 11, 2012
2763
m/z 757.34 (M++H). Anal. Calcd for C38H30N12O2Cl2: C, 60.24; H, 3.99; N, 22.19. Found: C, 60.27; H,
3.94; N, 22.15.
REFERENCES
1. L. X. Xiao and D. Q. Shi, Chin. J. Org. Chem., 2010, 30, 85.
2. Q. Y. Ren, Y. J. Liang, H. W. He, L. W. Fu, and Y. C. Gu, Bioorg. Med. Chem. Lett., 2009, 19,
6713.
3. S. Peyman, I. M. David, and D. Minoo, Mol. Divers., 2012, 16, 231.
4. G. Blanco and C. Peinador, Tetrahedron, 2008, 64, 1136.
5. Z. D. Fang and M. W. Ding, Heteroatom. Chem., 2008, 19, 266.
6. Y. W. Jo, W. B. Im, J. K. Rhee, M. J. Shim, W. B. Kim, and E. C. Choi, Bioorg. Med. Chem., 2004,
12, 5909.
7. S. Sun, L. Chen, and X. H. Yang, Chin. J. Chem., 2011, 29, 991.
8. J. F. Zhao, C. Xie, M. W. Ding, and H. W. He, Chem. Lett., 2005, 34, 1020.
9. R. Islam, N. Ashida, and T. Nagamatsu, Tetrahedron, 2008, 64, 9885.
10. Z. D. Fang and J. Q. Liu, Chin. J. Org. Chem., 2011, 31, 2102.
11. Z. D. Fang and J. Q. Liu, Chin. J. Org. Chem., 2012, 32, 197.
12. J. F. Zhao, C. Xie, M. W. Ding, and H. W. He, Synthesis, 2005, 2544.